Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Racial and Ethnic Differences in Amyloid PET Positivity in Individuals With Mild Cognitive Impairment or Dementia
Consuelo H. Wilkins, Charles Windon, Peggye Dilworth‐Anderson, et al.
JAMA Neurology (2022) Vol. 79, Iss. 11, pp. 1139-1139
Open Access | Times Cited: 79

Showing 1-25 of 79 citing articles:

Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
Clifford R. Jack, J. Scott Andrews, Thomas G. Beach, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 8, pp. 5143-5169
Open Access | Times Cited: 538
Lecanemab: Appropriate Use Recommendations
J Cummings, L Apostolova, G D Rabinovici, et al.
The Journal of Prevention of Alzheimer s Disease (2023)
Open Access | Times Cited: 383
Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging
Rioghna R. Pittock, Jeremiah A. Aakre, Anna Castillo, et al.
Neurology (2023) Vol. 101, Iss. 19
Open Access | Times Cited: 89
Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease
Suzanne E. Schindler, Douglas Galasko, Ana C. Pereira, et al.
Nature Reviews Neurology (2024) Vol. 20, Iss. 7, pp. 426-439
Open Access | Times Cited: 76
Alzheimer disease blood biomarkers: considerations for population-level use
Michelle M. Mielke, Nicole R. Fowler
Nature Reviews Neurology (2024) Vol. 20, Iss. 8, pp. 495-504
Closed Access | Times Cited: 26
Physical exercise, cognition, and brain health in aging
Nárlon Cássio Boa Sorte Silva, Cindy K. Barha, Kirk I. Erickson, et al.
Trends in Neurosciences (2024)
Closed Access | Times Cited: 23
The Bio‐Hermes Study: Biomarker database developed to investigate blood‐based and digital biomarkers in community‐based, diverse populations clinically screened for Alzheimer's disease
Richard C. Mohs, Douglas W. Beauregard, John Dwyer, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 4, pp. 2752-2765
Open Access | Times Cited: 21
Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup
Gil D. Rabinovici, D. S. Knopman, Javier Arbizu, et al.
Alzheimer s & Dementia (2025)
Open Access | Times Cited: 12
Updated Appropriate Use Criteria for Amyloid and Tau PET: A Report from the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup
Gil D. Rabinovici, D. S. Knopman, Javier Arbizu, et al.
Journal of Nuclear Medicine (2025), pp. jnumed.124.268756-jnumed.124.268756
Closed Access | Times Cited: 2
Donanemab: Appropriate use recommendations
G D Rabinovici, D. J. Selkoe, Suzanne E. Schindler, et al.
The Journal of Prevention of Alzheimer s Disease (2025), pp. 100150-100150
Open Access | Times Cited: 2
Donanemab for Alzheimer Disease—Who Benefits and Who Is Harmed?
Jennifer J. Manly, Kacie Deters
JAMA (2023) Vol. 330, Iss. 6, pp. 510-510
Closed Access | Times Cited: 40
The complex pathway between amyloid β and cognition: implications for therapy
William J. Jagust, Charlotte E. Teunissen, Charles DeCarli
The Lancet Neurology (2023) Vol. 22, Iss. 9, pp. 847-857
Open Access | Times Cited: 31
Plasma biomarkers for Alzheimer’s and related dementias: A review and outlook for clinical neuropsychology
Heather E. Dark, Michael R. Duggan, Keenan A. Walker
Archives of Clinical Neuropsychology (2024) Vol. 39, Iss. 3, pp. 313-324
Open Access | Times Cited: 14
Large‐scale deep proteomic analysis in Alzheimer's disease brain regions across race and ethnicity
Fatemeh Seifar, Edward J. Fox, Anantharaman Shantaraman, et al.
Alzheimer s & Dementia (2024)
Open Access | Times Cited: 11
Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD‐ADRD): Executive summary of recommendations for primary care
Alireza Atri, Bradford C. Dickerson, Carolyn Clevenger, et al.
Alzheimer s & Dementia (2024)
Open Access | Times Cited: 10
Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease
Antoine Leuzy, Ariane Bollack, Daniela Pellegrino, et al.
Alzheimer s & Dementia (2025) Vol. 21, Iss. 3
Open Access | Times Cited: 1
A call to address structural barriers to Hispanic/Latino representation in clinical trials on Alzheimer's disease and related dementias: A micro‐meso‐macro perspective
María P. Aranda, David X. Márquez, Dolores Gallagher‐Thompson, et al.
Alzheimer s & Dementia Translational Research & Clinical Interventions (2023) Vol. 9, Iss. 2
Open Access | Times Cited: 22
A Survey of Deep Learning for Alzheimer’s Disease
Qinghua Zhou, Jiaji Wang, Xiang Yu, et al.
Machine Learning and Knowledge Extraction (2023) Vol. 5, Iss. 2, pp. 611-668
Open Access | Times Cited: 22
Longitudinal amyloid and tau PET imaging in Alzheimer's disease: A systematic review of methodologies and factors affecting quantification
Ariane Bollack, Hugh Pemberton, Lyduine E. Collij, et al.
Alzheimer s & Dementia (2023) Vol. 19, Iss. 11, pp. 5232-5252
Open Access | Times Cited: 18
Eligibility Rates among Racially and Ethnically Diverse US Participants in Phase 2 and Phase 3 Placebo‐Controlled, Double‐Blind, Randomized Trials of Lecanemab and Elenbecestat in Early Alzheimer Disease
Joshua D. Grill, Charlene Flournoy, Shobha Dhadda, et al.
Annals of Neurology (2023) Vol. 95, Iss. 2, pp. 288-298
Open Access | Times Cited: 17
Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer’s disease
Matthew D. Howe, Karysa Britton, Hannah E. Joyce, et al.
Alzheimer s Research & Therapy (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 7
Participant diversity is necessary to advance brain aging research
Gagan S. Wig, Sarah Klausner, Micaela Y. Chan, et al.
Trends in Cognitive Sciences (2024) Vol. 28, Iss. 2, pp. 92-96
Open Access | Times Cited: 6
Racial and ethnic differences in plasma biomarker eligibility for a preclinical Alzheimer's disease trial
Doris P. Molina‐Henry, Rema Raman, Andy Liu, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 6, pp. 3827-3838
Open Access | Times Cited: 6
Altered limbic functional connectivity in individuals with subjective cognitive decline: Converging and diverging findings across Chinese and German cohorts
Xueyan Jiang, Xiaochen Hu, Marcel Daamen, et al.
Alzheimer s & Dementia (2023) Vol. 19, Iss. 11, pp. 4922-4934
Open Access | Times Cited: 16
Amyloid and Tau Prediction of Cognitive and Functional Decline in Unimpaired Older Individuals: Longitudinal Data from the A4 and LEARN Studies
Reisa A. Sperling, Michael Donohue, Robert A. Rissman, et al.
The Journal of Prevention of Alzheimer s Disease (2024)
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top